DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
- Citation:
- J Clin Oncol vol 42 (4) 399-409
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-internal-user
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 13
- Parents:
- 3123
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Bristol Myers Squibb (BMS), Genentech, Pfizer, and Sanofi
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233253, UG1CA233327, UG1CA233373, UG1CA180830 and U10CA180888 (SWOG), R01CA143237
- Corr. Author:
- Authors:
- Federico Innocenti Wancen Mu Xueping Qu Fang-Shu Ou Omar Kabbarah Charles David Blanke Alan P Venook Heinz-Josef Lenz Naim U Rashid
- Networks:
- CA011, CA824, LAPS-MN026, LAPS-NC007, OR013
- Study
- Alliance-A151813
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-80405
- Phases:
- N/A, 3
- Keywords:
- Humans, Bevacizumab, Cetuximab, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, Microsatellite Instability, Standard of Care, Mutation, Antineoplastic Combined Chemotherapy Protocols